BEN domain containing 3 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored BEND3P2 profile across patient tissues and cancer cell-line models. BEND3P2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BEND3P2 is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, BEND3P2 RNA expression shows 6,905 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, LUAD, and STAD as cancer lineages where BEND3P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BEND3P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BEND3P2 survival associations across molecular data types. BEND3P2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BEND3P2 RNA expression–survival associations across cancer types. High BEND3P2 expression shows unfavorable associations in KICH, but favorable associations in HNSC, ESCA, BLCA, LUAD and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for BEND3P2 RNA expression.
This table summarizes BEND3P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for BEND3P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BEND3P2 shows lower tumor expression in LUAD, LUSC, LIHC, KICH and CHOL and higher tumor expression in UCEC. The LUAD box plot shows higher BEND3P2 RNA expression in normal versus tumor tissue (log2 FC = −0.211, t-test p < 0.001).
This table shows molecular features associated with BEND3P2 in patient tissues and cancer cell lines. In patient samples, BEND3P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
